Early Development Services, PRA Health Sciences, Salt Lake City, Utah UT 84122 USA.
Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Curr Rev Clin Exp Pharmacol. 2022;17(1):72-80. doi: 10.2174/1574884716666210225083213.
Opioid analgesics used to treat pain can cause respiratory depression. However, this effect has not been extensively studied, and life-threatening, opioid-induced respiratory depression remains difficult to predict. We tested the ventilatory response to hypercapnia for evaluating the pharmacodynamic effect of a drug on respiratory depression.
We conducted a randomized, placebo-controlled, double-blind, crossover study on 12 healthy adult males. Subjects received 2 treatments (placebo and immediate-release oxycodone 30 mg) separated by a 24-hour washout period. Subjects inhaled a mixture of 7% carbon dioxide, 21% oxygen, and 72% nitrogen for 5 minutes to assess respiratory depression. Minute ventilation, respiratory rate, tidal volume, flow rate, end-tidal CO2, and oxygen saturation were recorded continuously at pre-dose and 30, 60, 120, and 180 minutes post-dose. The primary endpoint was the effect on the ventilatory response to hypercapnia at 60 minutes post-dose, as assessed by the slope of the linear relationship between minute ventilation and end-tidal CO2.
At 60 minutes post-dose, subjects had a mean slope of 2.4 in the oxycodone crossover period, compared to 0.1 in the placebo period (mean difference, 2.3; 95% CI: 0.2 to 4.5; p = 0.035). Statistical significance was likewise achieved at the secondary time points (30, 120, and 180 minutes post-dose, p <0.05).
This model for testing ventilatory response to hypercapnia discriminated the effect of 30 mg of oxycodone . placebo for up to 3 hours after a single dose. It may serve as a method to predict the relative effect of a drug on respiratory depression.
用于治疗疼痛的阿片类镇痛药可能会导致呼吸抑制。然而,这种作用尚未得到广泛研究,危及生命的阿片类药物引起的呼吸抑制仍然难以预测。我们测试了高碳酸血症时的通气反应,以评估药物对呼吸抑制的药效作用。
我们在 12 名健康成年男性中进行了一项随机、安慰剂对照、双盲、交叉研究。受试者接受了 2 种治疗(安慰剂和即释型羟考酮 30mg),间隔 24 小时洗脱期。受试者吸入 7%二氧化碳、21%氧气和 72%氮气的混合物 5 分钟,以评估呼吸抑制。在预给药和给药后 30、60、120 和 180 分钟,连续记录分钟通气量、呼吸频率、潮气量、流量、呼气末二氧化碳和氧饱和度。主要终点是评估 60 分钟时呼吸抑制对高碳酸血症通气反应的影响,通过分钟通气量和呼气末二氧化碳之间的线性关系的斜率来评估。
在羟考酮交叉期,受试者在给药后 60 分钟的斜率为 2.4,而在安慰剂期为 0.1(平均差异,2.3;95%置信区间:0.2 至 4.5;p=0.035)。在次要时间点(给药后 30、120 和 180 分钟)也达到了统计学意义(p<0.05)。
这种测试高碳酸血症通气反应的模型区分了单次给药后 3 小时内 30mg 羟考酮与安慰剂的作用。它可能成为预测药物对呼吸抑制相对作用的一种方法。